NCT05712187 - Phase 2b Study of ALTO-100 in MDD | Biotech Hunter

Enrollment

301

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

September 5, 2024

Study Completion Date

October 24, 2024

Conditions

Major Depressive Disorder

Interventions

DRUG

ALTO-100

ALTO-100 tablet BID

DRUG

Placebo

Placebo tablet BID

Trial Locations (34)

10022

Site 180, New York

10128

Site 210, New York

11229

Site 184, Brooklyn

21229

Site 151, Baltimore

29405

Site 157, North Charleston

32256

Site 204, Jacksonville

32801

Site 205, Orlando

33629

Site 212, Tampa

Site 213, Tampa

34613

Site 186, Brooksville

35294

Site 174, Birmingham

35801

Site 173, Huntsville

38119

Site 183, Memphis

39216

Site 108, Jackson

Site 171, Jackson

44145

Site 175, Westlake

46032

Site 137, Carmel

68562

Site 142, Lincoln

72211

Site 139, Little Rock

76104

Site 147, Fort Worth

77054

Site 120, Houston

77081

Site 172, Houston

80112

Site 185, Centennial

84020

Site 121, Draper

85226

Site 136, Chandler

87109

Site 178, Albuquerque

89102

Site 144, Las Vegas

91730

Site 179, Rancho Cucamonga

92056

Site 182, Oceanside

Site 188, Oceanside

92251

Site 181, Imperial

92626

Site 141, Costa Mesa

93703

Site 118, Fresno

95655

Site 116, Sacramento